Company moves to bigger grounds!, page-114

Which we can extrapolate forward knowing we have sold over $2.5m worth of cardiocel already as Rodne said in the AGM. Nobody will get the same answer as we extrapolate differently depending on how we see the centre uptake taking off. Unfortunately, all who is saying this is overvalued seem to be looking at this TODAY and not the future and most who say this is undervalued can't give proper reasoning- except the odd few. Their is only one main reason why this isn't going anywhere and that is because management will not give us the future revenue guide they expect.. Without this, we are out on a limb and we can only use our best guesstimates. Our vaccine division must be worth something, calculate the $ per last % we paid and work out the value of our vaccine division, nothing that has been worked on for this long should be worth $0. But the market wont ascribe value to it until they see positive phase 2 results because if the market believes you have a 50% chance of failure then the price is worth $0... What they might not understand is how this platform can be used for other things... again same argument though, worth nothing till proven.. especially in the ASX.

We need to see a very big % increase in cardiocel numbers this quarter and the next in order to move the price. I hope Admedus can saturate it into 200 centres by December 31st this year and also partner up on their next adapt product as well as a partner for the vaccine.